Search Results - "Wu, Tianshuang"

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Authors: Magnolo, Nina Soung, Jennifer Frew, John et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3415-3429. 15p.

Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime.

Authors: Artman, William J Nahum-Shani, Inbal Wu, Tianshuang et al.

Source: Biostatistics; Jul2020, Vol. 21 Issue 3, p432-448, 17p

Identifying a set that contains the best dynamic treatment regimes.

Authors: ERTEFAIE, ASHKAN TIANSHUANG WU LYNCH, KEVIN G. et al.

Source: Biostatistics; Jan2016, Vol. 17 Issue 1, p135-148, 14p

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.

Authors: Simpson, Eric L. Silverberg, Jonathan I. Prajapati, Vimal H. et al.

Source: Dermatology & Therapy. Aug2025, Vol. 15 Issue 8, p2061-2076. 16p.

Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial.

Authors: Tyring, Stephen Moore, Angela Morita, Akimchi et al.

Source: Clinical & Experimental Dermatology. Nov2024, Vol. 49 Issue 11, p1347-1355. 9p.

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

Authors: Alexis, Andrew F. Gooderham, Melinda Kwatra, Shawn G. et al.

Source: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2877-2887. 11p.

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Authors: Papp, Kim A. Lebwohl, Mark G. Puig, Lluís et al.

Source: American Journal of Clinical Dermatology. Sep2025, Vol. 26 Issue 5, p829-841. 13p.

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.

Authors: Strober, Bruce Armstrong, April Rubant, Simone et al.

Source: Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p2991-2996. 6p.

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.

Authors: Odnopozova, Liudmila Edin, Anton Sukharev, Alexey et al.

Source: Dermatology & Therapy. Sep2022, Vol. 12 Issue 9, p2063-2075. 13p.

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

Authors: Crowley, Jeffrey J. Langley, Richard G. Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p561-575. 15p.

Set Valued Dynamic Treatment Regimes.

Authors: Wu, Tianshuang

Committee Members: Murphy, Susan A; Wang, Lu; Tewari, Ambuj; He, Xuming

URL: http://hdl.handle.net/2027.42/133462

Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome.

Authors: Seewald, Nicholas J Kidwell, Kelley M Nahum-Shani, Inbal et al.

Source: Statistical Methods in Medical Research. Jul2020, Vol. 29 Issue 7, p1891-1912. 22p.

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

Authors: Strober, Bruce Bachelez, Hervé Crowley, Jeffrey et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2024, Vol. 38 Issue 5, p864-872. 9p.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Authors: Cestari TF Souza CDS Azulay-Abulafia L et al.

Source: Anais brasileiros de dermatologia [An Bras Dermatol] 2025 Mar-Apr; Vol. 100 (2), pp. 260-271. Date of Electronic Publication: 2024 Dec 07.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Elsevier España, S.L Country of Publication: Spain NLM ID: 0067662 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1806-4841 (Electronic) Linking ISSN: 03650596 NLM ISO Abbreviation: An Bras Dermatol Subsets: MEDLINE

Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.

Authors: Coates LC Abraham S Tillett W et al.

Source: Arthritis care & research [Arthritis Care Res (Hoboken)] 2022 Feb; Vol. 74 (2), pp. 259-267. Date of Electronic Publication: 2021 Dec 29.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Validation Study

Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101518086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2151-4658 (Electronic) Linking ISSN: 2151464X NLM ISO Abbreviation: Arthritis Care Res (Hoboken) Subsets: MEDLINE

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

Authors: Blauvelt A Teixeira HD Simpson EL et al.

Source: JAMA dermatology [JAMA Dermatol] 2021 Sep 01; Vol. 157 (9), pp. 1047-1055.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Authors: Papp KA Blauvelt A Puig L et al.

Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Dec; Vol. 89 (6), pp. 1149-1158. Date of Electronic Publication: 2023 Aug 06.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).

Authors: Stein Gold LF Bagel J Tyring SK et al.

Source: The British journal of dermatology [Br J Dermatol] 2023 Oct 25; Vol. 189 (5), pp. 540-552.

Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).

Authors: Blauvelt A Ladizinski B Prajapati VH et al.

Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Sep; Vol. 89 (3), pp. 478-485. Date of Electronic Publication: 2023 May 23.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

Authors: Blauvelt, Andrew Leonardi, Craig L. Gooderham, Melinda et al.

Source: JAMA dermatology Jun2020; Vol. 156 (6).

Journal Info: Publisher: American Medical Association ISSN: 2168-6068